China has a huge and rapidly growing elderly population, contributing to a rising incidence of thromboembolic disease.^[@R1]^ Warfarin is an effective and the most commonly used anticoagulant to prevent and treat thromboembolic disease worldwide. However, a particular challenge to the use of warfarin is its narrow therapeutic index with large individual variations in the daily dose requirement, often leading to either insufficient or excessive anticoagulation.^[@R2]^ These concerns, coupled with a lack of optimal warfarin dosing recommendations contribute to a low usage rate of anticoagulants (only 6.16% among the eligible patients) in China,^[@R3]^ compared with other countries. Low warfarin use may contribute to the high incidence of cardiovascular risk events in China.^[@R4],[@R5]^

A potential strategy to improve warfarin efficacy and safety is to account for individual genetic variations. The International Warfarin Pharmacogenetic Consortium^[@R5]^ has developed a predictive formula for personalized warfarin dosing to improve anticoagulation control. However, there are serious gaps in the science. First, there has only been a limited number of large, multicenter, randomized trials on genotype-guided dosing of warfarin in Western populations, including the EU-PACT study (European Pharmacogenetics of Anticoagulant Therapy), the COAG study (Clarification of Optimal Anticoagulation Through Genetics), and the randomized clinical GIFT (Genetic Informatics Trial),^[@R6]--[@R8]^ which have yielded conflicting results. Second, previous studies^[@R9]--[@R11]^ have shown that individual differences in warfarin outcomes are closely related to genetic factors such as *CYP2C9* and *VKORC1* (vitamin K epoxide reductase complex, subunit 1), but the effects of these genetic factors vary by race.^[@R12],[@R13]^ In white populations, *CYP2C9\*2* (rs1799853), *CYP2C9\*3* (rs1057910), and *VKORC1-1639G\>A* (rs9923231) are used to predict an appropriate warfarin dose, but *CYP2C9* rs1799853 is rare in Asian populations,^[@R14]^ while rs12777823 on chromosome 10 is a better predictor than *CYP2C9\*2* and *CYP2C9\*3* in selecting a warfarin dose in African populations.^[@R15]^ Observational studies^[@R16]--[@R18]^ suggest that *CYP2C9* rs1057910 and *VKORC1* rs9923231 are related to warfarin dose and bleeding risk in Chinese populations. To date, there has also been a particular dearth of large, well-designed warfarin clinical trials in Chinese populations, such that the clinical utility of a genotype-guided dosing of warfarin in Chinese populations is unclear.

Therefore, we designed a multicenter, randomized, single-blind, parallel-controlled trial called XY3-WAR (Warfarin Trial of the Third Xiangya Hospital, Central South University) to evaluate whether genotype-guided warfarin dosing is superior in achieving the outcomes of interest as compared with routine clinical dosing in Chinese adult patients with atrial fibrillation or deep vein thrombosis.

Methods
=======

The data that support the findings of this study are available from the corresponding author upon reasonable request. The study was approved by the Institutional Review Board of the Third Xiangya Hospital of Central South University and the institutional review board of each participating hospital. All subjects provided written informed consent. Full methods are available in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602).

Results
=======

Participants
------------

From September 2014 to January 2017, 686 eligible patients were invited to participate in the study; a total of 660 patients agreed to be enrolled and were randomly assigned to either a genotype-guided dosing group or a control group (n=330 each; Figure [1](#F1){ref-type="fig"}). The proportion of patients not genotyped on day 1 in the genotyping arm was 8.8% (29 of 330). These 29 patients were all genotyped on the second day of dosing. The participant enrollment summary at each study site is detailed in Table V in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602). A large majority of the participants (87.1%) had atrial fibrillation while the remainder (12.9%) had deep vein thrombosis. A summary of concomitant diseases and drug combinations of participants in each group is listed in Tables VI and VII in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602). Baseline data distribution was balanced between the 2 groups (Table [1](#T1){ref-type="table"}). The genotypic distribution conformed with Hardy-Weinberg equilibrium, except for *CYP2C9\*2*, where no polymorphism was identified in this study population.

###### 

Demographic and Baseline Clinical Characteristics of the Study Participants\*

![](hcg-13-e002602-g001)

![**Consort diagram detailing the total number of participants recruited, withdrawn, and analyzed.** \*A list of the exclusion criteria appears in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602). †Plans for surgery, discovery of cancer, or other health reasons.](hcg-13-e002602-g002){#F1}

We included 551 participants who had at least 13 days of international normalized ratio (INR) data in the final analysis. Specific reasons for participant withdrawal from the study are illustrated in Figure [1](#F1){ref-type="fig"}.

Primary Outcome Measure
-----------------------

The percentage of time in the therapeutic range (%TTR) in both groups increased with time; since the INR peaks at around day 13 and then plateaus, we included 551 participants who had at least 13 days of INR data in the %TTR analysis, %TTR was 58.8% in the genotype-guided dosing group as compared with 53.2% in the control group during the first 12 weeks. The difference was statistically significant (*P*=0.01), representing a difference of 5.6 percentage points (95% CI, 1.1--10.2) between the 2 groups. In the per-protocol analysis, %TTR in the genotype-guided group (239 participants) and the control group (233 participants) was 60.9% and 55.2%, respectively, which corresponds to a difference of 5.4 percentage points (*P*=0.02). In the intent-to-treat analysis, the corresponding value was 54.8% in the genotype-guided dosing group (309 participants) compared with 50.1% in the control group (316 participants; Table [2](#T2){ref-type="table"}). The difference between the 2 groups in the mean %TTR became apparent between days 5 and 10 (Figure [2](#F2){ref-type="fig"}).

###### 

Primary and Secondary Outcomes During the First 12 wk Between the 2 Groups\*
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![**Percentage of time in the therapeutic international normalized ratio (INR) range, Kaplan-Meier plots of time to reach therapeutic INR, and Kaplan-Meier plots of time to reach a stable warfarin dose.** **A**, Percentage of time in the therapeutic INR range during the first 12 wk by treatment groups (genotype-guided dosing group vs standard dosing group). **B**, Within 1 to 12 wk, percentages of patients with INR reaching therapeutic range in control and genotype-guided dosing groups. **C**, Within 1 to 12 wk, percentages of patients reaching a stable warfarin dose in control and genotype-guided dosing groups.](hcg-13-e002602-g004){#F2}

Secondary Outcome Measures
--------------------------

The trend of change in INR was similar between the 2 groups (Figure II in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602)). INR increased rapidly during the first 2 weeks, then declined slowly after 2 weeks where it stayed within the therapeutic range. The median time to reach the therapeutic INR was shorter in the genotype-guided group than in the control group (*P*\<0.001; Table [2](#T2){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). In this study, 233 participants in the genotype-guided dosing group (85.7%) and 221 participants in the control group (79.2%) reached a stable dose by 12 weeks, which was 2.4±1.0 and 2.5±0.9 mg, respectively, showing no significant differences between the 2 groups (Figure [2](#F2){ref-type="fig"}) nor in other secondary outcomes including the number of warfarin dose adjustment units, the incidence of INR ≥4, or the number of additional visits (Table [2](#T2){ref-type="table"}).

Within 1 to 4 weeks, %TTR was higher in the genotype-guided dosing group than in the control group (49.3% and 44.1%, respectively \[95% CI, 0.6--9.3\]; *P*=0.02). Within 1 to 8 weeks, %TTR was higher in the genotype-guided dosing group than in the control group (58.2% and 52.0%, respectively \[95% CI, 1.5--10.7\]; *P*=0.009). Within 1 to 12 weeks, %TTR was also higher in the genotype-guided dosing group than in the control group (60.5% and 55.2%, respectively \[95% CI, 0.3--9.7\]; *P*=0.04; Table 2). The results of line regression, cox regression, and logistic regression are presented in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602). The results of intent-to-treat analysis are presented in Table VIII in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602).

Adverse Event Analysis
----------------------

Adverse events were recorded throughout the study. A total of 652 participants were enrolled in safety outcome measures: 323 participants from the genotype-guided group and 329 participants from the control group. There was no significant difference in overall adverse events between the 2 groups (Table [2](#T2){ref-type="table"}). In all, 38 bleeding events (20 in the genotype-guided group and 18 in the control group), 25 mild bleeding events (14 in the genotype-guided group and 11 in the control group), 7 moderate bleeding events (4 in the genotype-guided group and 3 in the control group), and 6 severe bleeding events (2 in the genotype-guided group and 4 in the control group) were reported. One mortality was reported in each group. There was only 1 thromboembolic event recorded in the control group. There were no significant differences across the various safety parameters between the 2 groups (Table [2](#T2){ref-type="table"}). The results of logistic regression are presented in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602).

Subgroup Analysis Based on Genotyping and Age
---------------------------------------------

In the warfarin normal responder group, %TTR was significantly higher in the genotype-guided warfarin dosing group than in the control group (60.8% versus 48.9% \[95% CI of the group difference, 1.1--24.4\]; *P*=0.03; Table [3](#T3){ref-type="table"}; Figure III in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602)). However, there were no significant differences between the 2 groups among the warfarin highly sensitive and warfarin sensitive (Table [3](#T3){ref-type="table"}). The INR of participants in the genotype-guided group reached the therapeutic range faster than that of the control group among the sensitive and sensitive responders (*P*=0.02, *P*\<0.001; Table 3). The results of intent-to-treat analysis are presented in Table IX in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602).

###### 

Subgroup Analysis Based on Genotype\*
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In further subgroup analyses of related outcomes based on age, only the time to reach the therapeutic INR showed significant differences in the genotype-guided group in comparison with the control group both in patients \<60 years of age (*P*=0.01) or ≥60 years of age (*P*\<0.001). Other outcomes were not statistically significant between the genotype-guided group and the control group in both age groups (Table X in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602)). The results of intent-to-treat analysis are presented in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602) (Table XI in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602)).

All the results are similar between base model and the model adjusting for covariates in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602).

Discussion
==========

To our knowledge, our study is by far the largest randomized trial on genotype-guided dosing of warfarin in a Chinese population. Our results showed that genotype-guided dosing of warfarin increased the percentage of time in the therapeutic INR range (%TTR, the primary outcome) by 5.6% and reduced the time to reach a therapeutic INR. However, the time to reach a stable dose, the number of adjustment units in the dose of warfarin, incidence of INR ≥4, the number of additional clinic visits, and incidence of adverse events did not differ between the 2 groups.

Different from the COAG and GIFT studies, the control group in our trial was administrated according to the clinical routine. Our results are similar to those of the EU-PACT study, which suggested that genotype-based dosing can improve anticoagulant control during the initiation of warfarin therapy.^[@R6]^ However, the average %TTR of 55.9% in our study was lower than the reported 63.8% observed in the EU-PACT study. The risk of hemorrhage in our study was also significantly lower than that of the EU-PACT study (Table LVI in the [Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.119.002602)). This may be due to the fact that a loading dose was used in the EU-PACT study to reduce the time to reach a therapeutic INR but at the expense of an increased risk of excessive anticoagulation.^[@R19]^ Our study did not use a loading dose because clinicians in China are reluctant to use accelerated warfarin dosing regimens due to concerns about bleeding risk and the lack of evidence-based guidance for optimal warfarin dosing in Chinese populations. However, in contrast to the EU-PACT study, all of the secondary outcomes were not improved. One possible explanation for this difference in findings is that the frequency of actionable variants is much lower in a predominantly Chinese population. For example, the *CYP2C9\*2* haplotype was not detected, and \<20% of participants had an alternate allele in *VKORC1.* Therefore, because of the lower frequency of alternate alleles in these 2 genes, there may have been less opportunity to improve dosing. Similar to the influence of genetic polymorphisms with warfarin dose in blacks,^[@R15]^ additional alleles in *CYP2C9/VKORC1* that are more prevalent in a Chinese population may have affected trial outcomes, similarly *CYP4F2*,^[@R20]^ rs2108622, shows a mutant frequency of 32.9% to 48% in the Chinese population. It has been associated with influencing warfarin therapy. The *CYP4F2\*3* variant is associated with a modest increase in warfarin dose requirements, thereby the dosage for patients carried *CYP4F2* need to be adjusted accordingly. The number of dose titrations was used as the primary outcome in a noninferiority study by Syn et al^[@R21]^ in Singaporeans. Despite the primary outcome of our study was different from theirs, our results were consistent with them that pharmacogenomics-guided warfarin administration was superior to traditional administration.

To our knowledge, before our study, only 1 genotype-guided trial had been performed in a Chinese population in Taiwan.^[@R22]^ The results of the trial were inconclusive due to a small sample size (n=318) and problems in study design.

Distinct from previous studies,^[@R6],[@R7]^ our study further performed subgroup analyses by genotype. Our results revealed that only participants with genotypes *CYP2C9\*1/\*1* and *VKORC1* GG or GA benefited from the genotype-guided dosing of warfarin. This observation suggests that the current International Warfarin Pharmacogenetic Consortium formula derived from clinical studies in North America and Europe produced positive but inconsistent clinical results, and more studies are needed to refine the genotype-guided dosing of warfarin for the Chinese population. In particular, it is necessary to add more valuable genetic polymorphisms to guide the dosing of warfarin, such as *CYP4F2.* In an age subgroup analysis, only the time to reach therapeutic INR between the genotype-guided group and the control group was significantly different, and this difference existed in both age groups.

No significant differences existed in adverse events between the 2 treatment groups. Although 1 death occurred in each of the 2 groups, both participants had been diagnosed with hypertension. Analysis of cause of death showed that these 2 participants had uncontrolled hypertension, which might have caused intracerebral hemorrhage (the cause of death) while taking warfarin. Under the monitoring of the Independent ethics committee, in view of the 2 cases of death, our study modified the protocol. The reported rate of hemorrhagic complications observed in our study (5.8%) was much lower than the combined major/minor bleeding events (18%) reported for warfarin-treated Chinese patients in a community-based hospital.^[@R23]^ Our study findings provide assurance that with standard clinical monitoring of INR, warfarin can be safely used in Chinese populations.

Limitations
-----------

Our study had several limitations. First, although our study is by far the largest trial in a Chinese population and the second largest of all the published trials of this kind, future studies with even larger sample sizes are needed. The sample size is so small that more samples are needed to confirm the results of subgroup analysis. Additionally, we fell short of our originally targeted sample size, and the risk of an inflated type I error cannot be completely ruled out. The overall withdrawal rate within 13 days was 16.5%; however, this was consistent with the reported discontinuation rate of warfarin therapy observed in a large Chinese atrial fibrillation registry cohort study.^[@R24]^ The observed high discontinuation rate of warfarin therapy in China may be related to a lack of knowledge and overestimation of bleeding risk associated with warfarin therapy.^[@R25]^ Second, our study only included participants from Hunan province, China. However, the ethnic distribution of the population in Hunan province is similar to that of the nationwide ethnic distribution in China,^[@R26]^ and, therefore, the participants included in our study were likely to be a good representation of the Chinese population. Third, our study was not designed to generalize the study findings to ethnic minorities in China as only 0.3% of the study participants identified as ethnic minorities and there are 56 officially recognized ethnic groups in China.^[@R27]^ Although the same genes could be used to determine dose requirements in different ethnic groups,^[@R15],[@R28]^ the nongenetic-related ethnic factors also played an independent and important role in predicting warfarin dose.^[@R12],[@R29]^ Therefore, more work remains to be done to develop a robust ethnic and genotype-guided algorithm for improving warfarin dosing in all ethnic groups in China. Finally, it remains a possibility that additional unknown candidate genes affecting warfarin treatment response may exist. Their discovery awaits for future studies.

Conclusions
-----------

In conclusion, the results of this multicenter, randomized, single-blind, parallel-controlled trial demonstrate the utility of genotype-guided dosing of warfarin to optimize individual warfarin dose in Chinese populations. These findings, if further confirmed by future trials, can serve as a foundation for developing a robust, evidence-based, personalized dosing and monitoring strategy to maximize efficacy and minimize adverse events of warfarin therapy in Chinese populations.
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